Incyte Corp (INCY)

124.28
NASDAQ : Health Care
Prev Close 124.17
Day Low/High 123.02 / 124.80
52 Wk Low/High 68.03 / 153.15
Avg Volume 2.64M
Exchange NASDAQ
Shares Outstanding 204.59M
Market Cap 25.40B
EPS 0.60
P/E Ratio 229.94
Div & Yield N.A. (N.A)

Latest News

Sweet Sounds of Numbers; Have Faith: Jim Cramer's View

Sweet Sounds of Numbers; Have Faith: Jim Cramer's View

Cramer shares his views on the preponderance of evidence, and suggests having faith in interational strength.

Incyte's Immuno-oncology And Targeted Therapy Clinical Portfolio To Be Featured In More Than 15 Abstracts At The 2017 ASCO Annual Meeting

Incyte's Immuno-oncology And Targeted Therapy Clinical Portfolio To Be Featured In More Than 15 Abstracts At The 2017 ASCO Annual Meeting

Incyte Corporation (Nasdaq: INCY) announces that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American Society...

Turnarounds are Tenuous Things: Cramer's 'Mad Money' Recap (Wednesday 04/19/17)

Turnarounds are Tenuous Things: Cramer's 'Mad Money' Recap (Wednesday 04/19/17)

IBM's busted turnaround and difficult transition story shaved more than 50 points off the Dow, says Jim Cramer.

Wells Fargo Among 5 Stocks Insiders Are Loading Up On

Wells Fargo Among 5 Stocks Insiders Are Loading Up On

Insiders at Wells Fargo & Company, Incyte and three other companies have been scooping up shares of their own stock lately.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CUDA, ELS, EMN, FCFS, FSIC, HLF, INCR, PAYC, PBHC, PNR, SABR, SFLY, UTSI, VNOM, WB Downgrades: CUI, IGLD, INCY, MTSC, RUBI, TSEM Initiations: AFI Read on to get TheStreet Quant Ratings' detailed report:

Incyte To Report First Quarter Financial Results

Incyte To Report First Quarter Financial Results

Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 10:00 a.

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Wall Street Ends Its Losing Streak As Corporate Earnings Take Focus

Stocks close in positive territory Monday ahead of a big week for U.S. corporate earnings.

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Closing Bell: Stocks End Higher As Corporate Earnings Take Focus

Stocks remained in positive territory breaking a three-day losing streak ahead of U.S. corporate earnings this week, despite mounting tension between North Korea and the U.S.

Stocks That Are Changing Direction

Stocks That Are Changing Direction

These charts are showing bullish or bearish reversals.

Cramer: Have Faith in International Strength

Cramer: Have Faith in International Strength

Because there are other things that will take the wind out of your sails.

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks Higher Ahead of Earnings From Netflix, United Airlines

Stocks rise on Monday ahead of a big week for U.S. corporate earnings, including reports Monday from Netlfix and United Airlines.

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data

Stocks Higher as Wall Street Focuses on Earnings and Mixed Economic Data

Stocks rise on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Biotech Movers: OncoMed, Incyte, Omeros

Biotech Movers: OncoMed, Incyte, Omeros

OncoMed Pharmaceuticals, Incyte and Omeros were among the biotech stock movers in premarket trading on Monday.

Eli Lilly Stock Falls Premarket After FDA Rejects Arthritis Drug Due to Safety Concerns

Eli Lilly Stock Falls Premarket After FDA Rejects Arthritis Drug Due to Safety Concerns

The drug was expected to bring in more than $1 billion in sales by 2020.

Stock Futures Turn Higher as Wall Street Watches North Korea, Awaits Earnings

Stock Futures Turn Higher as Wall Street Watches North Korea, Awaits Earnings

Stock futures turn higher on Monday ahead of a big week for U.S. corporate earnings and as the U.S. issues a warning to North Korea.

5 Things You Must Know Before the Market Opens Monday

5 Things You Must Know Before the Market Opens Monday

U.S. stock futures are lower Monday following economic data that came in soft and after the U.S. warns North Korea that its patience with the rogue nation is running out.

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

U.S. FDA Issues Complete Response Letter For Baricitinib

U.S. FDA Issues Complete Response Letter For Baricitinib

Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.

Incyte Stock Rises Following Morgan Stanley Upgrade

Incyte Stock Rises Following Morgan Stanley Upgrade

Morgan Stanley raised Incyte's price target to $150.

Here Is Why Jim Cramer Is Bullish on Incyte

Here Is Why Jim Cramer Is Bullish on Incyte

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Incyte INCY shares.

Incytes: Cramer's Top Takeaways

Incytes: Cramer's Top Takeaways

Jim Cramer cites Incyte's solid fundamentals.

Bank Earnings Are at a Critical Turning Point: Cramer's 'Mad Money' Recap (Wednesday 4/12/17)

Bank Earnings Are at a Critical Turning Point: Cramer's 'Mad Money' Recap (Wednesday 4/12/17)

Loss of bank leadership and the recent pullback are major factors in what's ailing the markets, says Jim Cramer.

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views

Doug Kass shares his thoughts on Tesla and the second quarter.